NLS Pharmaceutics Secures Hong Kong Patent for Diabetes Tech
Ticker: NCEL · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, pharmaceuticals, diabetes, collaboration
TL;DR
NLS Pharma gets HK patent for diabetes cell tech with Kadimastem.
AI Summary
On September 4, 2025, NLS Pharmaceutics Ltd. announced a patent granted in Hong Kong for cell-selection and enrichment technology related to its IsletRx product for diabetes patients. This patent was developed in collaboration with Kadimastem.
Why It Matters
This patent strengthens NLS Pharmaceutics' intellectual property portfolio for its diabetes treatment, potentially enhancing its market position and future commercialization efforts.
Risk Assessment
Risk Level: medium — The filing is a routine announcement of a patent grant, but the actual commercial impact and competitive landscape for this technology are not detailed, introducing some uncertainty.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Kadimastem (company) — Collaborator on patent
- IsletRx (product) — Diabetes treatment technology
- September 4, 2025 (date) — Date of press release
- Hong Kong (location) — Jurisdiction of patent grant
FAQ
What is the specific technology covered by the Hong Kong patent?
The patent covers cell-selection and enrichment technology for IsletRx, a treatment for diabetes patients.
Who is NLS Pharmaceutics collaborating with on this patent?
NLS Pharmaceutics is collaborating with Kadimastem on this patent.
When was the press release announcing this patent issued?
The press release was issued on September 4, 2025.
What is the Commission file number for NLS Pharmaceutics Ltd.?
The Commission file number is 001-39957.
Does NLS Pharmaceutics file annual reports under Form 20-F?
Yes, NLS Pharmaceutics indicates it files annual reports under Form 20-F.
Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-09-04 08:37:49
Filing Documents
- ea0255971-6k_nlspharma.htm (6-K) — 9KB
- ea025597101ex99-1_nlspharma.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 27KB
- 0001213900-25-084281.txt ( ) — 70KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 4, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3